USPSTF’s Wanda Nicholson: Screening saves lives, but screening alone won’t fix disparities in cancer deaths

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The U.S. Preventive Services Task Force’s latest draft recommendation on breast cancer screening is based in part on data on racial disparities in breast cancer mortality.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Matthew Bin Han Ong
Associate Editor
Table of Contents


Patient-reported outcomes data from the phase III NATALEE trial, presented at the European Society for Medical Oncology Virtual Plenary, show that a broad population of patients with stage 2 and 3 hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer maintained health-related quality of life during treatment with Kisqali (ribociclib) plus endocrine therapy.
Matthew Bin Han Ong
Associate Editor